According to Zydus Lifesciences's latest financial reports the company has $0.24 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-03-31 | $0.14 B | -67.99% |
2022-03-31 | $0.45 B | 199.43% |
2021-03-31 | $0.15 B | -6.04% |
2020-03-31 | $0.16 B | 25.88% |
2019-03-31 | $0.12 B | -52.91% |
2018-03-31 | $0.27 B | 11.12% |
2017-03-31 | $0.24 B | 93.05% |
2016-03-31 | $0.12 B | 6.93% |
2015-03-31 | $0.11 B | 17.1% |
2014-03-31 | $0.10 B | -17.85% |
2013-03-31 | $0.12 B | 35.13% |
2012-03-31 | $92.31 M | 39.51% |
2011-03-31 | $66.17 M | 18.25% |
2010-03-31 | $55.95 M | 12.91% |
2009-03-31 | $49.56 M | 113.5% |
2008-03-31 | $23.21 M | 1.24% |
2007-03-31 | $22.93 M | 133.12% |
2006-03-31 | $9.83 M | -29.91% |
2005-03-31 | $14.03 M | 37.59% |
2004-03-31 | $10.19 M |